Skip to main content

Taysha Gene Therapies, Inc.

TSHA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001806310

In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Taysha Gene Therapies, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of TSHA: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders5452−2
Shares13.9M19.4M+5.44M (+39.1%)
Value$27.0M$43.8M+$16.8M (+62.0%)

New holders (14)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to TSHA in Q4 2022
InstitutionSharesValue% of portfolio
Altium Capital Management LP359,051$811.5K0.42%
Bank of Montreal202,199$459.0K0.00%
Susquehanna International Group, LLP160,724$363.2K0.00%
Marshall Wace, LLP69,296$156.6K0.00%
Cubist Systematic Strategies, LLC40,301$91.1K0.00%
Redwood Wealth Management Group, LLC35,600$80.5K0.10%
Caas Capital Management LP22,994$52.0K0.01%
Jump Financial, LLC16,917$38.2K0.00%
Kovitz Investment Group Partners, LLC15,000$34.0K0.00%
Maven Securities LTD15,000$33.9K0.01%
Commonwealth Equity Services, LLC13,725$31.0K0.00%
Northwestern Mutual Wealth Management Co10,000$22.6K0.00%
Group One Trading, L.P.444$1.00K0.00%
Money Concepts Capital Corp115$2600.00%

Sold out (16)

Institutions that held Taysha Gene Therapies, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.